Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 3/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609688 | 0.93 | L3MBTL1 (0.42) | L3MBTL1FKBP1AF2ELANECTSG | |
| SCHEMBL329869 | 0.87 | F2 (0.45) | L3MBTL1F2ELANECTSGCTRC | |
| SCHEMBL4433517 | 0.86 | MEN1 (0.41) | L3MBTL1F2ELANECTSGCTRC | |
| SCHEMBL7044546 | 0.84 | MEN1 (0.42) | L3MBTL1FKBP1ASMN1; SMN2CYP1A1GAA | |
| SCHEMBL8773329 | 0.84 | POLB (0.47) | L3MBTL1POLBDRD3KCNH2 | |
| SCHEMBL8089341 | 0.83 | FKBP1A (0.41) | L3MBTL1FKBP1AF2ELANECTSG | |
| SCHEMBL10416569 | 0.83 | FKBP1A (0.41) | L3MBTL1FKBP1ADRD3GAA | |
| SCHEMBL8112327 | 0.82 | L3MBTL1 (0.37) | L3MBTL1FKBP1APOLBCYP1A1DRD3 | |
| SCHEMBL7299264 | 0.82 | DRD3 (0.33) | F2ELANECTSGCTRCPER2 | |
| SCHEMBL22604425 | 0.82 | PER2 (0.36) | L3MBTL1F2ELANECTSGCTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20090042762-A1 | CLEANER COMPOSITION FOR REMOVAL OF LEAD-FREE SOLDERING FLUX, RINSING AGENT FOR REMOVAL OF LEAD-FREE SOLDERING FLUX, AND METHOD FOR REMOVAL OF LEAD-FREE SOLDERING FLUX | ARAKAWA CHEMICAL INDUSTRIES, LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1295935-B1 | DETERGENT COMPOSITION | ARAKAWA CHEM IND (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-7018964-B2 | The cleaning composition of this invention comprises, as effective components, a compound (A) represented by the formula (1) and a nonionic surfactant (B): polyoxyethylene glycol phosphate | ARAKAWA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-28 | — | — | US | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20030181349-A1 | The cleaning composition of this invention comprises, as effective components, a compound (A) represented by the formula (1) and a nonionic surfactant (B): polyoxyethylene glycol phosphate | ARAKAWA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1295935-A1 | DETERGENT COMPOSITION | Arakawa Chemical Industries, Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-0718291-B1 | Method for the preparation of triazole compounds | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-07-08 | — | — | EP | disclosed |
| US-5567825-A | Method for the preparation of a triazole compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-10-22 | — | — | US | disclosed |
| EP-0718291-A1 | Method for the preparation of triazole compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | L3MBTL1 1834/4885FKBP1A 1270/4885F2 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.